November 26, 2024

New Member: Welcome in our cluster to Cell Signaling Technology Europe B.V.

New Member: Welcome in our cluster to Cell Signaling Technology Europe B.V.
Go back

Cell Signaling Technology (CST) is a private, family-owned company, founded by scientists and dedicated to providing high-quality research tools to the biomedical research community.

CST empowers scientists worldwide with innovative, high-quality tools to advance discovery. Beyond science, CST prioritizes responsibility by partnering with communities and minimizing environmental impact. As the first life science member of 1% for the Planet, CST is committed to achieving net-zero emissions by 2029. Dedicated to good science and doing good, CST drives solutions for global challenges with care and integrity.

If you would like to learn more, please visit their Website.
Looking forward to your active participation!

Our latest News

discover more
Member2Member: Where expertise meets the community

Member2Member: Where expertise meets the community

Every company in the bioRN network has a story to tell. More importantly, every company has knowledge that can help others move faster, avoid mistakes and spark new collaborations. That is the idea behind bioRN’s Member2Member series. Instead of traditional company presentations, Member2Member opens the doors to our member organisations and puts their expertise centre […]

read more
BioMed X and Boehringer Ingelheim Expand XSeed Labs to Advance Next-Generation Eye Therapies

BioMed X and Boehringer Ingelheim Expand XSeed Labs to Advance Next-Generation Eye Therapies

Ridgefield, CT, USA, July 9, 2026 – BioMed X, a leading innovation engine for pharma, and Boehringer Ingelheim today announced the launch of a new research team at XSeed Labs, the established innovation incubator embedded within Boehringer’s U.S. R&D headquarters in Ridgefield, Connecticut. The newly established research team, Team NIB (New Platform for Next-Generation Intraocular […]

read more
Clinical Trial on Mild Stroke: Inpatient or Outpatient Treatment?

Clinical Trial on Mild Stroke: Inpatient or Outpatient Treatment?

Researchers at Heidelberg University’s Faculty of Medicine are investigating a new care model for older adults with mild strokes at the Heidelberg University Hospital’s Department of Neurology. The Joint Federal Committee (G-BA) is funding the ARTIFICE study with approximately 2.4 million euros. Full Text in German below. Klinische Studie zu leichtem Schlaganfall: stationär oder ambulant […]

read more

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp